Testing ctDNA to detect minimal residual disease in GI cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses deep sequencing of selected tumor mutations to measure ctDNA in patients with locally advanced or metastatic gastrointestinal cancers. ctDNA is analyzed to identify minimal residual disease or early progression during or after preoperative chemotherapy, with the goal of guiding treatment decisions. The approach relies on sequencing mutations found in primary tumors and monitoring their appearance in blood. The study aims to validate ctDNA as a biomarker for molecular relapse/progression in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Consent to participate in the study
* Patients with esophageal, gastric, or pancreatic cancer, stage 0-2
* Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy
* Patients with metastatic disease treated with first- to third-line palliative systemic therapy

Exclusion Criteria:

* not specified

Where it's running

• Masaryk Memorial Cancer Institute
  Brno, Czechia Recruiting

Study contacts

• Principal investigator: Radka Lordick Obermannová, MD, Doc, PhD — Masaryk Memorial Cancer Institute
• Study coordinator: Martina Lojová, PhD
• Email: martina.lojova@mou.cz
• Phone: +420543136232

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Gastric and pancreatic cancer patients see if IR199 with Ga-68 and I-131 is safe and how it distributes in the body

  This study tests the safety and how the radio-labeled IR199 distributes in the body of adults with Claudin 18.2-positive gastric or pancreatic cancer.

  Recruiting Early Phase 1 Huashan Hospital · Shanghai · NCT07707531

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.